Letters Archives – Page 5 of 12 – Treatment Action Group

Appeals to legislators to prioritize tuberculosis (TB) in plans for fiscal year 2017

November 4, 2019
Chad Cipiti

TAG and other U.S.-based NGOs and civil society groups sent several appeals to legislators to prioritize tuberculosis (TB) in plans for fiscal year 2017 in line with the White House’s recently released National Action Plan for Combating Multidrug-Resistant Tuberculosis. Letters to three key House and Senate subcommittees—the Labor, Health and Human Services, Education, and Related Agencies Subcommittee, the Defense Subcommittee, and the Subcommittee on State, Foreign Operations, and Related Programs.

A Lower Price for Rifapentine Is Just a Start – Communities Need More Than Discounts to Access TB Preventive Therapy

October 31, 2019
Jason Kirk

October 31, 2019 — Civil society and community-based organizations issued this letter welcoming the availability of lower-priced rifapentine, which is an essential medicine for preventing TB. However, while all the organizations agree that this discount is a step forward, they're…

TAG Comment in Response to Proposed Rulemaking: Visas: Ineligibility Based on Public Charge Grounds

October 30, 2019
Jason Kirk

As an organization dedicated to ensuring equitable access to critical health services to individuals and communities affected by HIV/AIDS, tuberculosis (TB), and hepatitis C virus (HCV), Treatment Action Group (TAG) strongly opposes the proposed changes regarding “public charge,” published in the Federal Register on October 11, 2019 (the proposed rule).

Open Letter to Cepheid: Time to Lower the Price of Xpert Cartridges to US $5

October 21, 2019
Jason Kirk

Letter from Organizations and Individuals to Cepheid asking them to reduce the price of Xpert MTB/RIF and Xpert MTB/RIF Ultra cartridges to US $5, inclusive of service and maintenance.

TAG Submitted Testimony to the House Committee on Oversight and Reform Hearing on “HIV Prevention Drug: Billions in Corporate Profits After Millions in Taxpayer Investments”

May 16, 2019
Chad Cipiti

TAG submitted testimony for the record for the hearing, "HIV Prevention Drug: Billions in Corporate Profits after Millions in Taxpayer Investments" at the request of members of the House Oversight and Reform Committee.

Letter Urging Support at UN Commission on Narcotic Drugs for Measures to Prevent & Treat Hep C Among People Who Use Drugs

March 20, 2019
Chad Cipiti

TAG and our community partners submitted letters urging the US Delegation to the UN Commission on Narcotic Drugs to express support for draft resolution E/CN.7/2019/L.4.

Letters of Support – Protecting Equitable Health for all New Yorkers, Including Undocumented Adults and Those with Temporary Protected Status (TPS)

March 5, 2019
Chad Cipiti

TAG submitted the following letters of support to the NY State assembly Health Committee Members to support Assembly Bills A.3316 (S. 1809) and A.5974 (S. 3900).

Public Comment on NIDA Strategic Plan for Research at the Intersection of HIV/AIDS and Substance Use, Misuse, and Addiction

January 25, 2019
Chad Cipiti

TAG recently submitted a public comment to the National Institute on Drug Abuse (NIDA) at the National Institute of Health to inform a strategic plan it is developing to support research at the intersection of HIV and drug use.

Public Comment on Identifying the Root Causes of Drug Shortages and Finding Enduring Solutions

January 22, 2019
Chad Cipiti

TAG recently submitted this public comment on Identifying the Root Causes of Drug Shortages and Finding Enduring Solutions, highlighting the need to mitigate national supply challenges and shortages of critical TB drugs.

Public Comment on USPSTF Draft Recommendations for PrEP and HIV Screening

January 14, 2019
Chad Cipiti

The US Preventive Services Task Force (USPSTF) recently released draft recommendations regarding HIV screening for all Americans ages 15-65, including pregnant women, and pre-exposure prophylaxis (PrEP) for individuals highly vulnerable to HIV infection.